

Welcome to the Surveillance **A**fter Extremity Tumor surger**Y** (SAFETY) Trial December Enrolment Update!

## RECRUITMENT UPDATE


We are pleased to report that as of 5 December 2022, **183** participants have been enrolled in the SAFETY trial.

Congratulations to **Dr. Vivek Ajit Singh** and the research team at **University of Malaya Medical Centre** in **Kuala Lumpur, Malaysia**, for opening to enrolment in the SAFETY trial!

Congratulations to **Marcos Galli Serra** and the research team at **Hospital Universitario Austral** in **Buenos Aires, Argentina**, for enrolling their first SAFETY trial participant!

Site	Country	Enrolled Since Last Update	Enrolled to Date	Projected Yearly Enrolment	2022 Enrolment
Juravinski Hospital and Cancer Centre	Canada	0	54	15	17
Hôpital Maisonneuve-Rosemont	Canada	1	20	10	10
Oregon Health and Science University	USA	3	14	15	14
Centro Traumatologico Ortopedico Hospital	Italy	1	11	10	5
Huntsman Cancer Institute	USA	1	8	12	3
Leiden University Medical Centre	NLD	0	7	12	4
Hospital de Clínicas de Porto Alegre	Brazil	1	7	8	2
L'Hôtel-Dieu de Quebec	Canada	0	6	5	2
Parkview Cancer Institute	USA	0	6	10	6
University of Florida Health Shands Hospital	USA	0	6	10	0
Medical University Graz	Austria	0	5	8	1
Cleveland Clinic	USA	1	5	10	2
University of California Davis Medical Center	USA	0	5	10	2
McGill University Health Centre	Canada	0	4	5	2
The Ottawa Hospital	Canada	0	4	5	4
Albany Medical Center	USA	0	4	8	1
Holden Comprehensive Cancer Centre	USA	1	4	6	1
Nova Scotia Health	Canada	0	3	5	1
NYU Langone Orthopaedic Hospital	USA	0	3	5	0
St. Vincent's Hospital Melbourne	Australia	0	2	8	2
Hartford HealthCare	USA	0	2	6	2
Montefiore Medical Centre	USA	0	2	6	1
Hospital Universitario Austral	Argentina	1	1	8	1
Mount Sinai Hospital	Canada	0	0	12	0
University of Malaya Medical Centre	Malaysia	0	0	10	0
Texas Tech Health Sciences Center El Paso	USA	0	0	10	0
Virginia Cancer Specialists	USA	0	0	10	0
<b>Total</b>		<b>10</b>	<b>183</b>	<b>239</b>	<b>83</b>

## 2022 ENROLMENT GOAL



## STUDY RESOURCES

You can find study resources at [www.SAFETYrct.com](http://www.SAFETYrct.com) by logging into the SAFETY Investigator section of our website:

Username: siteinvestigators

Password: SAFETYInvestigators1!

# SAFETY UPDATES

## UNIVERSITY OF MALAYA MEDICAL CENTRE OPENS FOR ENROLMENT

Congratulations to Dr. Vivek Ajit Singh and the research team for University Malaya Medical Centre for opening to enrolment! We are excited to expand the SAFETY trial to Malaysia.



## HELP US REACH 200 PARTICIPANTS

We are only 17 patients away from reaching our 2022 enrolment target of 200 participants!

Please ensure all eligible participants are being approached for consent. If you are unsure of the eligibility of a patient, reach out to the Methods Centre and we will be happy to answer your questions.

Congratulations to Hôpital Maisonneuve-Rosemont for reaching their enrolment target for 2022!

# SAFETY PEARLS

## TIPS FOR APPROACHING PATIENTS

- Provide patients with a study information sheet prior to surgery to give them time to fully review, consider, and ask any questions.
- Remind patients that if they do participate in the study, they can still schedule clinic visits as needed.
- Inform patients that they will receive care for any possible adverse events, just as they would outside of the study.
- Let patients know that we have enrolled 183 patients across 27 sites spanning 9 countries and 5 continents. This means at least 27 ethics committees have deemed the study safe.

## SURVEILLANCE VISITS FOR PATIENTS WITH RECURRENT DISEASE

Please remember to conduct surveillance visits for patients with recurrent disease, even if they may be under the care of another medical professional. These visits can be in person, or via telephone or teleconference. The Surveillance Visit form, questionnaires, and/or Costs Diary should still be completed, along with any of the as-needed forms (ex. Local/Systemic Recurrence forms, Radiation/Systemic Therapy logs, etc.).

## TIPS FOR COMPLETING SCREENING FORMS

- If an otherwise eligible patient declines to participate, please select *No* for Q16 (*Has the patient provided informed consent?*). Do not write declined to participate on Q15.
- For cases where the patient declined, please provide the reason the patient declined to participate in the *If no, specify* box (e.g., they wanted more/less frequent imaging, they did not want to complete the forms, etc.).
- If a patient is deemed ineligible or missed, please select *N/A* for Q16 to indicate that the patient was not approached for consent. Do not write a reason in the *If no, specify* box.
- Please use the comments section in Q20 if you would like to further explain the reason(s) the patient was excluded.

## 2022 Q4 SITE PAYMENTS

The Methods Centre will be processing the fourth quarter site payments this month. Database queries will be updated this week. Please take some time to address them. If you have any questions, please contact Hadia Farrukh at [farrukhh@mcmaster.ca](mailto:farrukhh@mcmaster.ca)

# METHODS CENTRE CONTACTS

If you have questions about any aspect of the SAFETY trial, please contact us:

**Dr. Michelle Ghert**, Principal Investigator  
[ghertm@mcmaster.ca](mailto:ghertm@mcmaster.ca)

**Tricia Schneider\***, Senior Project Manager  
[schnep@mcmaster.ca](mailto:schnep@mcmaster.ca)

**Tess Hudson**, Primary Project Manager  
[hudsontc@mcmaster.ca](mailto:hudsontc@mcmaster.ca)

**Hadia Farrukh**, Research Assistant  
[farrukhh@mcmaster.ca](mailto:farrukhh@mcmaster.ca)

\* Tricia is currently on maternity leave. Please contact Tess with any study correspondence.